📌 Key Takeaways
- On August 20, 2026, Revance and Teoxane announced FDA approval of RHA Redensity® Eye —
the first HA filler in the U.S. specifically indicated for infraorbital hollows (under-eye volume loss). - The pivotal trial’s FDA-documented responder rate was 79.0% at 12 weeks vs. 9.8% in the untreated control group;
the manufacturer separately reported 93% aesthetic improvement at 3 months — two figures measured by different criteria. - This is the first U.S. infraorbital trial to include Patient-Reported Outcomes (PRO) as a co-primary endpoint,
per the manufacturer. - The press release explicitly cites GLP-1 therapy-related facial fat loss as a growing driver of demand
for under-eye correction.
“My under-eyes look hollow lately — is it aging, or dark circles?”
If that question sounds familiar, a regulatory milestone announced this month is worth understanding.
On August 20, 2026, Revance Therapeutics and Swiss manufacturer Teoxane announced FDA approval of RHA Redensity® Eye —
an HA (hyaluronic acid) filler indicated specifically for infraorbital hollows in adults aged 22 and older.
The approval targets moderate-to-severe volume loss beneath the eye.
The press release also flags a broader market shift:
the under-eye area is described as one of the regions most susceptible to fat loss
in patients undergoing GLP-1 receptor agonist therapy (Ozempic, Wegovy, Mounjaro).
As weight-loss medications reshape bodies — and faces — aesthetic medicine is adapting.
INDEX
- Under-Eye Hollows vs. Dark Circles vs. Tear Troughs — Why the Distinction Matters
- What Is RHA Redensity Eye? Two Defining Features
- Reading the Clinical Data Accurately — What “79%” and “93%” Each Mean
- The GLP-1 Connection — Why This Approval Lands Now
- What to Confirm Before Seeking Treatment
- Summary
- Frequently Asked Questions
Under-Eye Hollows vs. Dark Circles vs. Tear Troughs — Why the Distinction Matters
Under-eye concerns fall into three distinct categories.
Confusing them leads to treatments that miss the mark.
Dark Circles
Caused by pigmentation, visible vasculature, or shadowing.
Subtypes (brown, blue, black) have different origins and require different treatments.
Fillers often do not resolve true dark circles.
Subtypes (brown, blue, black) have different origins and require different treatments.
Fillers often do not resolve true dark circles.
Tear Trough
A groove running along the lower eyelid margin.
Common even in younger patients, and anatomically distinct from the broader infraorbital hollow.
Common even in younger patients, and anatomically distinct from the broader infraorbital hollow.
Infraorbital Hollow ← This approval’s indication
A broader zone of volume deficiency below the orbital rim,
caused by age-related or weight-loss-related fat and soft tissue reduction.
This area moves with every facial expression,
demanding a filler material that can flex and recover without distortion.
caused by age-related or weight-loss-related fat and soft tissue reduction.
This area moves with every facial expression,
demanding a filler material that can flex and recover without distortion.
Most complaints of “looking tired or aged around the eyes” correspond to this third category.
Fillers are a valid treatment option — but until now, no HA gel had been specifically designed and FDA-approved for this zone.
What Is RHA Redensity Eye? Two Defining Features
💡 What Is PNT (Preserved Network Technology)?
Developed by Teoxane (Switzerland), PNT uses a thermal-free, uniform cross-linking process
that preserves the natural structure of hyaluronic acid chains.
The result is described as a “resilient HA” — one that moves with facial expressions
rather than resisting them.
For a high-mobility area like the under-eye, this material design is clinically relevant.
Developed by Teoxane (Switzerland), PNT uses a thermal-free, uniform cross-linking process
that preserves the natural structure of hyaluronic acid chains.
The result is described as a “resilient HA” — one that moves with facial expressions
rather than resisting them.
For a high-mobility area like the under-eye, this material design is clinically relevant.
Feature 1 — First U.S. infraorbital trial to include PRO as a co-primary endpoint
PRO (Patient-Reported Outcome) measures whether patients themselves perceive improvement —
not just the treating physician.
Conventional filler trials have relied exclusively on clinician-graded scales.
According to Revance, this is the first U.S. infraorbital hollow study
to elevate PRO to co-primary endpoint status.
It means the approval is grounded in both physician assessment and patient experience.
not just the treating physician.
Conventional filler trials have relied exclusively on clinician-graded scales.
According to Revance, this is the first U.S. infraorbital hollow study
to elevate PRO to co-primary endpoint status.
It means the approval is grounded in both physician assessment and patient experience.
Feature 2 — Highest dynamic strength and extensibility among under-eye HA fillers (manufacturer claim)
Revance states that RHA Redensity Eye offers the highest dynamic strength and extensibility
among HA fillers for the under-eye area.
This claim is based on manufacturer data, not independent third-party comparative research.
Readers should weigh it accordingly.
among HA fillers for the under-eye area.
This claim is based on manufacturer data, not independent third-party comparative research.
Readers should weigh it accordingly.
Reading the Clinical Data Accurately — What “79%” and “93%” Each Mean
Two numbers circulate in coverage of this approval.
They are not interchangeable.
📊 Two Data Points — Different Sources, Different Criteria
79.0%Responder rate at 12 weeks — FDA Instructions for Use (IFU), P170002S050D
Randomized, evaluator-blinded, untreated-control, multicenter, prospective trial.
Untreated control group: 9.8%. Statistically significant difference confirmed.
Randomized, evaluator-blinded, untreated-control, multicenter, prospective trial.
Untreated control group: 9.8%. Statistically significant difference confirmed.
93%Patients showing aesthetic improvement at 3 months — Revance press release, August 20, 2026
Duration of effect cited as up to 12 months.
Evaluation criteria and time points differ from the IFU figure; direct comparison is not valid.
Duration of effect cited as up to 12 months.
Evaluation criteria and time points differ from the IFU figure; direct comparison is not valid.
On safety, the FDA IFU documents the following:
No treatment-related serious adverse events.
No delayed adverse events, no vascular occlusion, no granuloma or delayed inflammatory reactions.
Common side effects were injection-site redness, swelling, pain, and bruising —
consistent with the standard filler safety profile.
The GLP-1 Connection — Why This Approval Lands Now
The press release contains a sentence that deserves attention:
From the Revance / Teoxane Press Release — August 20, 2026
“The under-eye area has emerged as an important aesthetic consideration,
as it is one of the regions where fat loss is commonly observed
in patients undergoing GLP-1 therapy.”
as it is one of the regions where fat loss is commonly observed
in patients undergoing GLP-1 therapy.”
Note: This reflects Revance’s market assessment.
The approved indication is not limited to GLP-1 users.
The approved indication is not limited to GLP-1 users.
💡 GLP-1 Therapy and Facial Volume Loss
GLP-1 receptor agonists — including semaglutide (Ozempic / Wegovy) and tirzepatide (Mounjaro) —
produce rapid, significant weight loss.
As total body fat decreases, facial fat and soft tissue diminish as well.
The under-eye area, temples, and cheeks are particularly prone to visible hollowing.
The resulting complaint — “my body is slimmer but my face looks older” —
is generating a new category of demand within aesthetic medicine.
GLP-1 receptor agonists — including semaglutide (Ozempic / Wegovy) and tirzepatide (Mounjaro) —
produce rapid, significant weight loss.
As total body fat decreases, facial fat and soft tissue diminish as well.
The under-eye area, temples, and cheeks are particularly prone to visible hollowing.
The resulting complaint — “my body is slimmer but my face looks older” —
is generating a new category of demand within aesthetic medicine.
Demand for facial volume restoration among GLP-1 users is measurably rising.
The timing of RHA Redensity Eye’s approval aligns with this shift.
Aesthetic medicine is actively developing a response to what weight-loss drugs leave behind on the face.
What to Confirm Before Seeking Treatment
⚠️ Regulatory Status Outside the U.S.
RHA Redensity Eye holds FDA approval in the United States.
Regulatory clearance in other countries — including Japan, the EU, and Australia —
must be verified independently.
Under-eye filler injections are performed globally,
but the specific product, indication, and regulatory status vary by market and clinic.
RHA Redensity Eye holds FDA approval in the United States.
Regulatory clearance in other countries — including Japan, the EU, and Australia —
must be verified independently.
Under-eye filler injections are performed globally,
but the specific product, indication, and regulatory status vary by market and clinic.
📌 Three Questions to Ask Before Any Under-Eye Filler Consultation
①“Is my concern a dark circle, tear trough, or infraorbital hollow?
Please assess which category applies before recommending treatment.”
Please assess which category applies before recommending treatment.”
②“Is the product you plan to use approved by the relevant regulatory authority in this country,
or is this an off-label application?”
or is this an off-label application?”
③“The under-eye area is vascularly dense.
What is your protocol for managing vascular occlusion,
and does this facility have hyaluronidase on hand for emergency reversal?”
What is your protocol for managing vascular occlusion,
and does this facility have hyaluronidase on hand for emergency reversal?”
Kenichi Adachi, Editor-in-Chief
Under-eye hollowing is one of the most common complaints I hear from patients in their late 30s and beyond.
It happens with natural aging — and it accelerates sharply after rapid weight loss on GLP-1 therapy.
What makes this approval notable is that it combines two things rarely seen together:
a purpose-built formulation for this specific anatomy,
and a trial design that actually asks patients whether they felt the difference.
FDA approval does not mean the product is available — or approved — where you live.
Before any under-eye filler, confirm three things:
the regulatory status of the product in your country,
your injector’s documented experience in the periorbital zone,
and the clinic’s emergency reversal protocol.
The under-eye is one of the most anatomically demanding sites in facial aesthetics.
Kenichi Adachi, Editor-in-Chief
Summary
- RHA Redensity® Eye received FDA approval on August 20, 2026,
indicated for infraorbital hollows in adults aged 22 and older.
Manufactured by Teoxane (Switzerland); distributed in the U.S. by Revance. - The pivotal trial was randomized, evaluator-blinded, untreated-controlled, multicenter, and prospective.
FDA IFU-documented responder rate: 79.0% at 12 weeks (untreated control: 9.8%).
Manufacturer-reported figure: 93% at 3 months, with effects lasting up to 12 months.
These two figures use different evaluation criteria and cannot be directly compared. - First U.S. infraorbital hollow trial to include PRO as a co-primary endpoint (per manufacturer).
Safety profile per FDA IFU: no serious treatment-related adverse events,
no vascular occlusion, no granuloma or delayed inflammatory reactions. - The press release explicitly links the product’s market opportunity to GLP-1-related facial fat loss —
reflecting a broader industry shift as weight-loss medications reshape aesthetic demand. - Regulatory status outside the U.S. must be confirmed independently.
The periorbital zone is anatomically complex;
injector experience and emergency reversal capability are non-negotiable prerequisites.
Frequently Asked Questions
Are there non-filler options for infraorbital hollows?
Yes. Alternatives include autologous fat grafting, biostimulators (e.g., Sculptra, Radiesse),
and surgical orbital fat repositioning (blepharoplasty).
Fillers offer immediacy and reversibility (via hyaluronidase),
but if the primary concern is pigmentation-based dark circles rather than volume loss,
fillers will not resolve the issue.
Accurate diagnosis by an experienced clinician is the essential first step.
and surgical orbital fat repositioning (blepharoplasty).
Fillers offer immediacy and reversibility (via hyaluronidase),
but if the primary concern is pigmentation-based dark circles rather than volume loss,
fillers will not resolve the issue.
Accurate diagnosis by an experienced clinician is the essential first step.
Can I get under-eye filler while on GLP-1 medications like Ozempic or Wegovy?
No universal contraindication guideline currently exists.
However, during periods of rapid weight change, the required filler volume and aesthetic outcome
can shift significantly as facial fat continues to redistribute.
Many clinicians recommend waiting until body weight stabilizes
before pursuing facial volume restoration.
Disclose your GLP-1 use to both your prescribing physician and your aesthetic provider.
However, during periods of rapid weight change, the required filler volume and aesthetic outcome
can shift significantly as facial fat continues to redistribute.
Many clinicians recommend waiting until body weight stabilizes
before pursuing facial volume restoration.
Disclose your GLP-1 use to both your prescribing physician and your aesthetic provider.
Is RHA Redensity Eye available outside the United States?
RHA Redensity Eye currently holds FDA approval in the United States.
Availability and regulatory clearance in other markets — including the EU, UK, Japan, and Australia —
must be confirmed with local regulatory authorities or directly with the clinic.
Before any treatment, ask explicitly whether the product is approved for this indication
in your country, or whether it would be used off-label.
Availability and regulatory clearance in other markets — including the EU, UK, Japan, and Australia —
must be confirmed with local regulatory authorities or directly with the clinic.
Before any treatment, ask explicitly whether the product is approved for this indication
in your country, or whether it would be used off-label.
Sources:
1. Revance / Teoxane. Press Release. PRNewswire. August 20, 2026. prnewswire.com
2. RHA Redensity® Eye Instructions for Use (IFU). P170002S050D. (Trial design, primary endpoints, safety data.)
3. Jafar et al. Aesthet Surg J Open Forum. 2024;22:6:ojae069. (GLP-1 therapy and facial fat loss.)
